Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/12/26
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 05/06/26
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in AdultsGlobeNewsWire • 03/23/26
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) CandidateGlobeNewsWire • 03/18/26
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 02/24/26
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal VaccinesGlobeNewsWire • 02/11/26
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026GlobeNewsWire • 02/10/26
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 02/02/26
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 01/29/26
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate VaccineGlobeNewsWire • 01/22/26
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in AdultsGlobeNewsWire • 12/08/25
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding StudyGlobeNewsWire • 11/04/25
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and ServicesGlobeNewsWire • 09/30/25
Vaxcyte, Inc. (PCVX) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/08/25
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized DoseGlobeNewsWire • 09/03/25